| NRX PHARMACEUTICALS |
| USA |
| Gesundheit |
| US6294442099 / A4091K |
| B1Q (Frankfurt) / NRXP (NASDAQ) |
| FRA:B1Q, ETR:B1Q, B1Q:GR, NASDAQ:NRXP |
| - |
| https://www.nrxpharma.com.. |
|
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for central nervous system disorders with high unmet medical need. The company concentrates on severe psychiatric and neurological condit..
>Volltext.. |
| 111.21 Mio. EUR |
| 106.21 Mio. EUR |
| 1.99 Mio. EUR |
| -14.65 Mio. EUR |
| -21.3 Mio. EUR |
| -1.11 EUR |
| 0.81 Mio. EUR |
| 5.83 Mio. EUR |
| -12.96 Mio. EUR |
| 0.27 |
| - |
| 4.69% |
| - |
| - |
| - |
| - |
| NRX PHARMACEUTICALS, NRX PHARMA, NRX PHARMACEUTICAL |
| 07.08.26 |
|